Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ABUS
- Price
- 4.16
- Stock movement down
- -0.15 (-3.61%)
- Company name
- Arbutus Biopharma Corp
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 771.22M
- Ent value
- 769.12M
- Price/Sales
- 52.80
- Price/Book
- 9.96
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -32.52%
- 1 year return (CAGR)
- 21.15%
- 3 year return (CAGR)
- 10.77%
- 5 year return (CAGR)
- -0.68%
- 10 year return (CAGR)
- 2.38%
Last updated: 2026-02-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ABUS does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 52.80 |
| Price to Book | 9.96 |
| EV to Sales | 52.66 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 192.32M |
| EPS (TTM) | -0.22 |
| FCF per share (TTM) | -0.24 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 14.61M |
| Gross profit (TTM) | -3.17M |
| Operating income (TTM) | -55.40M |
| Net income (TTM) | -42.28M |
| EPS (TTM) | -0.22 |
| EPS (1y forward) | -0.23 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -21.73% |
| Operating margin (TTM) | -379.27% |
| Profit margin (TTM) | -289.45% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 22.41M |
| Net receivables | 905.00K |
| Total current assets | 97.44M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 13.48M |
| Total assets | 97.71M |
| Accounts payable | 1.01M |
| Short/Current long term debt | 922.00K |
| Total current liabilities | 5.18M |
| Total liabilities | 20.31M |
| Shareholder's equity | 77.40M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -45.27M |
| Capital expenditures (TTM) | 86.00K |
| Free cash flow (TTM) | -45.36M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -54.62% |
| Return on Assets | -43.27% |
| Return on Invested Capital | -54.25% |
| Cash Return on Invested Capital | -58.20% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.18 |
| Daily high | 4.25 |
| Daily low | 3.85 |
| Daily Volume | 2.03M |
| All-time high | 30.94 |
| 1y analyst estimate | 5.79 |
| Beta | 0.72 |
| EPS (TTM) | -0.22 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 26 Feb 2026 |
Downside potential
Loading...
Downside potential data
| ABUS | S&P500 | |
| Current price drop from All-time high | -86.55% | -0.89% |
| Highest price drop | -97.19% | -56.47% |
| Date of highest drop | 9 Oct 2019 | 9 Mar 2009 |
| Avg drop from high | -75.20% | -10.86% |
| Avg time to new high | 137 days | 12 days |
| Max time to new high | 3001 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
771.22M
Marketcap category
Small-cap
Description
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Employees
44
Website
Investor relations
-
SEC filings
CEO
William H. Collier
Country
USA
City
Warminster
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page